KRYS (Krystal Biotech) E10: $-0.37 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KRYS Krystal Biotech Inc KRYS
55 GF Score
Price $332.92
GF Value $329.79
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Krystal Biotech E10?

Krystal Biotech KRYS +1.78% 55 E10 is $-0.37 as of Jun. 2026. GuruFocus rates KRYS with a GF Score™ of 55/100 and a GF Value™ of $329.79 (Fairly Valued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Krystal Biotech's adjusted earnings per share data for the three months ended in Jun. 2026 was $1.790. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-0.37 for the trailing ten years ended in Jun. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-12), Krystal Biotech's current stock price is $332.915. Krystal Biotech's E10 for the quarter that ended in Jun. 2026 was $-0.37. Krystal Biotech's Shiller PE Ratio of today is .


Krystal Biotech  (NAS:KRYS) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Krystal Biotech E10 Related Terms


Krystal Biotech E10 Historical Data

* Premium members only.

The historical data trend for Krystal Biotech's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Krystal Biotech E10 Chart

Krystal Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Krystal Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -0.37

KRYS vs NUVL, HALO, APGE: E10 Comparison

For the Biotechnology subindustry, Krystal Biotech's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Krystal Biotech Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Krystal Biotech's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Krystal Biotech's Shiller PE Ratio falls into.


KRYS
55GF Score
Krystal Biotech Inc KRYS
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Krystal Biotech E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Krystal Biotech's adjusted earnings per share data for the three months ended in Jun. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=1.79/333.9520*333.9520
=1.790

Current CPI (Jun. 2026) = 333.9520.

Krystal Biotech Quarterly Data

per share eps CPI Adj_EPS
201609 -0.075 241.428 -0.104
201612 -0.147 241.432 -0.203
201703 -0.116 243.801 -0.159
201706 -0.087 244.955 -0.119
201709 -1.260 246.819 -1.705
201712 -0.135 246.524 -0.183
201803 -0.210 249.554 -0.281
201806 -0.220 251.989 -0.292
201809 -0.260 252.439 -0.344
201812 -0.280 251.233 -0.372
201903 -0.290 254.202 -0.381
201906 -0.370 256.143 -0.482
201909 -0.250 256.759 -0.325
201912 -0.310 256.974 -0.403
202003 -0.310 258.115 -0.401
202006 -0.370 257.797 -0.479
202009 -0.490 260.280 -0.629
202012 -0.530 260.474 -0.680
202103 -0.740 264.877 -0.933
202106 -0.740 271.696 -0.910
202109 -0.700 274.310 -0.852
202112 -0.950 278.802 -1.138
202203 -1.990 287.504 -2.311
202206 -1.100 296.311 -1.240
202209 -1.170 296.808 -1.316
202212 -1.250 296.797 -1.406
202303 -1.760 301.836 -1.947
202306 -1.250 305.109 -1.368
202309 2.790 307.789 3.027
202312 0.310 306.746 0.337
202403 0.030 312.332 0.032
202406 0.530 314.175 0.563
202409 0.910 315.301 0.964
202412 1.520 315.605 1.608
202503 1.200 319.799 1.253
202506 1.290 322.561 1.336
202509 2.660 324.800 2.735
202512 1.700 324.054 1.752
202603 1.830 330.213 1.851
202606 1.790 333.952 1.790

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-0.37 mean?
Krystal Biotech (KRYS) has a E10 of $-0.37 as of Jun. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Krystal Biotech and its competitors.
Is Krystal Biotech's E10 too high?
Krystal Biotech's current E10 is $-0.37. Overall, Krystal Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's E10 compare to NUVL and HALO?
Krystal Biotech's E10 of $-0.37 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Krystal Biotech and its competitors. Krystal Biotech's current E10 is $-0.37. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (KRYS) is currently considered Fairly Valued. The stock's GF Value™ is $329.79, compared to a current price of $332.92 — trading 0.9% above its estimated fair value. The current E10 is $-0.37. Krystal Biotech's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Krystal Biotech (KRYS), the current E10 is $-0.37 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Krystal Biotech (KRYS) Overvalued in 2026?

Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued. The current stock price of $332.92 is trading 0.9% above its estimated GF Value™ of $329.79. GuruFocus considers Krystal Biotech to be Fairly Valued.

Key valuation signals for KRYS:

  • E10: $-0.37
  • GF Value™: $329.79 vs. price of $332.92 (0.9% above fair value)
  • GF Score™: 55/100 with 2 warning signs

No single metric tells the full story. See the KRYS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Krystal Biotech Business Description

Other Exchanges 1KRYS:Italy4KB:Germany
Address 2100 Wharton Street, Suite 701, Pittsburgh, PA, USA, 15203
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
55GF Score

Get the complete analysis for KRYS

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$332.92
Price
$329.79
GF Value